Inhaled Receptor Decoys: Efficacy Against SARS-CoV-2 in Monkey Preclinical Models (IMAGE)

Juntendo University Research Promotion Center

Inhaled Receptor Decoys: Efficacy Against SARS-CoV-2 in Monkey Preclinical Models

Caption

Engineered ACE2 decoy with high affinity and an IgG1 Fc domain demonstrated potent neutralization against Omicron subvariants, including emerging strains. The ability to escape mutants and display therapeutic activity in a primate model was demonstrated for the first time, which suggests its potential as a promising strategy against immune-evading SARS-CoV-2 variants. Inhaled aerosolized decoys also improved treatment outcomes, highlighting their potential non-invasive role in enhancing COVID-19 therapies.

Credit

Toru Okamoto, Juntendo University

Usage Restrictions

Toru Okamoto, Juntendo University

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.